Canagliflozin

Generic Name: Canagliflozin

Brand Names: Invokamet, Invokana

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₅FO_₅S

CAS Number: 842133-18-0

Unique Ingredient Identifier: 6S49DGR869

Background: Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...

Indication: This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine

Associated Therapies: -

Clinical Trials

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

Phase 2

Recruiting

Conditions: Acute Kidney Injury

Interventions: Other: Other anti-diabetic drug or no anti-diabetic drug
Drug: dapagliflozin
Drug: empagliflozin
Drug: canagliflozin

First Posted Date: 2024-07-30

Last Posted Date: 2024-12-04

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 264

Registration Number: NCT06528405

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: DPP4 inhibitor
Drug: 2nd generation Sulfonylurea
Drug: Liraglutide
Drug: Canagliflozin
Drug: Saxagliptin

First Posted Date: 2023-10-25

Last Posted Date: 2023-10-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 239990

Registration Number: NCT06099067

Locations: 🇸🇪
Research Site, Gothenburg, Sweden

Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

Phase 4

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Mulberry Twig Alkaloid Tablet
Drug: Canagliflozin

First Posted Date: 2023-05-12

Last Posted Date: 2023-05-12

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 60

Registration Number: NCT05856578

Locations: 🇨🇳
Jianhua Ma, Nanjing, China

Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Conditions: Type 2 Diabetes Mellitus With Complication

Interventions: Drug: Pioglitazone
Drug: Canagliflozin

First Posted Date: 2022-08-24

Last Posted Date: 2022-08-24

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 80

Registration Number: NCT05513729

Locations: 🇨🇳
First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shannxi, China

Renal Mechanism of SGLT2 Inhibition

Phase 2

Recruiting

Conditions: Type 2 Diabetes
Diabetic Kidney Disease

Interventions: Drug: canagliflozin
Drug: Aminohippurate Sodium Inj 20%

First Posted Date: 2022-08-19

Last Posted Date: 2022-11-03

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT05507892

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 1 locations

Canagliflozin Targeting Vascular Inflammation

Phase 2

Recruiting

Conditions: Diabetes Type 2
Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Canagliflozin

First Posted Date: 2022-06-22

Last Posted Date: 2024-12-11

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 24

Registration Number: NCT05427084

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Not Applicable

Conditions: Type 2 Diabetes Mellitus With Complication

Interventions: Drug: Canagliflozin
Drug: Pioglitazone

First Posted Date: 2022-06-16

Last Posted Date: 2022-09-21

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 80

Registration Number: NCT05422092

Canagliflozin in Patients With Acute Decompansted Heart Failure

Phase 3

Completed

Conditions: Chronic Heart Failure
Acute Heart Failure
Diabetes Mellitus

Interventions: Drug: Canagliflozin
Drug: Empagliflozin

First Posted Date: 2022-05-06

Last Posted Date: 2024-07-11

Lead Sponsor: October 6 University

Target Recruit Count: 142

Registration Number: NCT05364190

Locations: 🇪🇬
National heart institute, Giza, Egypt

Cognitive Protective Effect of Newer Antidiabetic Drugs

Conditions: Type 2 Diabetes

Interventions: Drug: Dapagliflozin
Drug: Empagliflozin
Drug: Canagliflozin
Drug: Sitagliptin
Drug: Saxagliptin
Drug: Linagliptin
Drug: Vildagliptin

First Posted Date: 2022-04-26

Last Posted Date: 2022-07-26

Lead Sponsor: Alexandria University

Target Recruit Count: 100

Registration Number: NCT05347459

Locations: 🇪🇬
Alexandria University, Alexandria, Egypt

Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.

Not Applicable

Recruiting

Conditions: Hiv
PreDiabetes

Interventions: Drug: Canagliflozin
Drug: Placebo

First Posted Date: 2021-11-26

Last Posted Date: 2022-03-08

Lead Sponsor: xiaolong zhao

Target Recruit Count: 218

Registration Number: NCT05135039

Locations: 🇨🇳
Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV: A Randomized Controlled Trial., Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy